Clinical trials: Support Program
Multiple Sclerosis, Relapsing-Remitting
A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data
This was an observational, non-interventional, real world study involving secondary use of de-identified aggregate data from patients prescribed ofatumumab, collected by the Kesimpta Go Program in Canada.
- Trial name
- CAPES (NCT06854341)
- Where
- United States
- Volunteers
- 5,448 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus - Poor Control
Continuous Glucose Monitoring, Diabetes Education, and Peer Support for Management of Uncontrolled Type 2 Diabetes
This research study is investigating whether a diabetes virtual group visit program using a continuous glucose monitor (CGM) can help improve glucose levels and quality of life in individuals with uncontrolled type 2 diabetes.
- Trial name
- COMPASS (NCT07054125)
- Testing
- Education, lifestyle counseling, and peer support
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Whole Endo
Crohn's Disease, Ulcerative Colitis (UC)
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.
- Conditions
- Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Psoriatic Arthritis
- Trial name
- IMPROVE (NCT03223012)
- Where
- 15 sites in Portugal
- Volunteers
- 116 people
- Sponsor
- AbbVie
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- 3DUTCH (NCT02817594)
- Where
- 9 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- AbbVie
Relapsing-remitting Multiple Sclerosis
Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS
A 6 months prospective, randomized, multicenter, controlled, parallel-group, open-label study in RRMS patients to assess the impact of an individualized patient support program (PSP) on treatment satisfaction and to evaluate…
- Trial name
- STAY (NCT01709812)
- Testing
- individualized patient support program, Standard care
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
The interferon-free combination regimen of ombitasvir/paritaprevir/ritonavir/ with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- CITRINE (NCT02803138)
- Testing
- Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin
- Where
- 18 sites in Israel
- Volunteers
- 256 people
- Sponsor
- AbbVie
Parkinson's Disease
Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal Gel
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- FACILITATECARE (NCT04500106)
- Where
- 13 sites in Australia, Israel and 2 more
- Volunteers
- 41 people
- Sponsor
- AbbVie
Multiple Sclerosis
A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone
To compare the effectiveness of a 90-day Copaxone® adherence enhancement program for a sample of MS patients who are at high risk of nonadherence and receive support from Shared Solutions® and their MS Center versus those who…
- Trial name
- NCT00240006
- Testing
- Shared Solutions® plus MS Center v. Shared Solutions®
- Volunteers
- 307 people
- Sponsor
- Teva Neuroscience, Inc.
Lysosomal Disease
A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico
During the COVID-19 pandemic, home treatment for conditions such as Fabry, Gaucher or Hunter became important because it is easier for people to stick to their treatment if medicines that need to be given as infusion (called…
- Trial name
- NCT07494058
- Testing
- No intervention
- Where
- Mexico
- Volunteers
- 232 people
- Sponsor
- Takeda
Early Memory Loss, Mild Cognitive Impairment
NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)
This study will be an observational study in which patients who have been prescribed CerefolinNAC® are invited to participate in surveys regarding their experiences with CerefolinNAC®.
- Conditions
- Early Memory Loss, Mild Cognitive Impairment, Alzheimer's Disease, Vascular Dementia
- Trial name
- NCT01370954
- Testing
- CerefolinNAC®
- Where
- United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Pamlab, Inc.
HIV Infections
Quantitative and Qualitative Research for "mHealth Program to Support People Living With HIV Across the HIV Care Continuum"
The goal of this randomized control trial (RCT) is to assess the effectiveness of Amp, a mobile health (mHealth) app designed to improve outcomes along the HIV care continuum for young Black men who have sex with men (YBMSM)…
- Trial name
- VSS (NCT06181916)
- Testing
- Amp
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sentient Research
Lung Diseases, Interstitial (in Pediatric Populations), Childhood Interstitial Lung Disease (chILD)
A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD)
This Expanded Access Program (EAP) is intended to facilitate the availability of OFEV® (nintedanib) to children and adolescents with chronic fibrosing interstitial lung disease (ILD) on top of current standard of care treatment…
- Trial name
- NCT05624281
- Testing
- nintedanib
- Sponsor
- Boehringer Ingelheim
Health Behavior, Behavioral Activation
Mobile Behavioral Activation Program With Wearable Sensors and Secure Activity Verification
This study evaluates a mobile-integrated behavioral activation program designed to help adults improve their daily productivity, motivation, and task engagement.
- Conditions
- Health Behavior, Behavioral Activation, Sedentary Behavior
- Trial name
- MBAP-X (NCT07382804)
- Testing
- Behavioral: Mobile Behavioral Activation App, Mobile App + Wearable Activity Sensor, Mobile App + Wearable Sensor + Secure Activity Verification Layer
- Where
- United States
- Volunteers
- 227,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Rheumatoid Arthritis, Ankylosing Spondylitis
Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)
The objective of this post-marketing observational study (PMOS) was to evaluate the effectiveness of adalimumab plus the AbbVie Care 2.0 patient support program in participants with rheumatoid arthritis (RA), ankylosing…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
- Trial name
- VALUE (NCT02750800)
- Testing
- Adalimumab, AbbVie Care 2.0
- Volunteers
- 427 people
- Sponsor
- AbbVie
Hepatitis C, Chronic, Hepacivirus
Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)
Several psychiatric adverse events (eg, depression, fatigue, psychoses, behavior troubles, anxiety, irritability, deteriorated concentration, and insomnia) that are likely to occur during the treatment course with PegIntron plus…
- Trial name
- NCT00723892
- Testing
- Peginterferon alfa-2b (PegIntron), Rebetol (Ribavirin), Psychotherapy support program
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
The Performance of Patient Support Program in Early Stage Breast Cancer
The purpose of this study is to compare the 1-year adherence to upfront adjuvant AI for postmenopausal, early stage breast cancer in the two observational arms; Standard Treatment and Standard Treatment plus PSP arm after one year
- Trial name
- ARI NIS (NCT00769080)
- Where
- 13 sites in China
- Volunteers
- 524 people
- Sponsor
- AstraZeneca
Multiple Sclerosis
Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis
This 1-arm, open-label, multicentric, observational study aims to collect subject centric information in line with routine care.
- Trial name
- AIMS (NCT01080573)
- Where
- United Kingdom
- Volunteers
- 1,257 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Prostate Cancer, Psychosocial Stressor
Feasibility of Technology-Based SSIP in Prostate Cancer Patients
The goal of this pilot study is to assess the perceived usability of a smartphone application called WINGS targeting psychosocial distress and well-being in prostate cancer patients and their social network.
- Trial name
- NCT05720832
- Testing
- WINGS-IP1 Smartphone Application
- Where
- Switzerland
- Volunteers
- 27 people
- Sponsor
- Wings Health AG
Type 2 Diabetes
Evaluation of a Digital Diabetes Self-Management Education and Support Program
The goal of this study is to examine the efficacy of an integrated solution, defined as a combination of the Abbott FreeStyle Libre 14-day CGM sensor and the Omada care team's receipt of real-time, continuous glucose data from…
- Trial name
- NCT05368454
- Testing
- Online Diabetes Self-Management Education and Support (DSMES) Program, Standard of Care
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Omada Health, Inc.
Depressive Disorder, Major
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER).
- Trial name
- NCT00401726
- Testing
- Venlafaxine ER, Dialogues Time to Talk Program
- Where
- 44 sites in United States
- Volunteers
- 537 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer